Participate in Research
Interested in research? Check out the current Bronchiectasis and NTM studies listed below.
The Bronchiectasis and NTM Research Registry is available to researchers conducting studies and/or clinical trials. Researchers not who are not part of the Bronchiectasis Research Consortium will go through an application process which involves Advisory Committee approval for the use of the Registry. The Registry can be used for recruitment and/or data analysis.
Below are some Bronchiectasis/NTM research studies and/or clinical trials that are currently being conducted. Please refer to the links in the description of each listing for more information (i.e. whether or not they are open for enrollment). For more opportunities to participate in research/clinical trials visit www.clinicaltrials.gov.
BRONCHIECTASIS STUDIES/CLINICAL TRIALS
Study Name: A Multicenter Study to Evaluate how Safe and Effective Pulmaquin® is in treating people with Non-Cystic Fibrosis Bronchiectasis with Chronic Lung Infections due to the bacteria Pseudomonas Aeruginosa
Study Purpose: To evaluate how safe and effective Pulmaquin is in the treatment of people with Non-Cystic Fibrosis Bronchiectasis and chronic lung infection. The amount of time to first pulmonary exacerbation after study enrollment will be one of the primary measures.
For more information, please visit: HTTP://WWW.ARADIGM.COM
Study Sponsor: Aradigm Corporation
NTM STUDIES/CLINICAL TRIALS
Study Name: A Randomized, Open Label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections caused by Mycobacterium avium complex (MAC) that are refractory to treatment
CONVERT is a clinical research study designed to evaluate an investigational medication—Liposomal Amikacin for Inhalation (LAI)—in adult patients with Nontuberculous Mycobacterial (NTM) lung infection caused by Mycobacterium avium Complex (MAC), who have not experienced success with previous treatments. The CONVERT study will take place in approximately 150 locations in North America, Europe, Asia-Pacific, and Australia.
Patients must be 18 years of age or older at screening, and fulfill other eligibility criteria, including the willingness to adhere to a multi-drug treatment regimen during the course of the study.
For more information, see visit www.ConvertResearchStudy.com and/or https://clinicaltrials.gov/ct2/show/NCT02344004. For questions or to request additional information, email NTMstudy@hudsonglobal.com or call 866-825-3418.
Study Sponsor: Insmed Incorporated
Below are some opportunities for those interested in lending their voice for issues related to living with Bronchiectasis, NTM, and/or other related conditions.
Duke University is conducting a survey to help better understand how patients feel about sharing their health information and to understand the most important questions that patients want answered about their medical devices. To learn more about this opportunity, click here.
The European Lung Foundation would like to find out how to make air travel easier for people who require assistance with breathing, so that their lung condition does not cause any additional stress or discomfort. To learn more about this opportunity, click here.